TITLE

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

AUTHOR(S)
Tack, J.; Müller-Lissner, S.; Bytzer, P.; Corinaldesi, R.; Chang, L.; Viegas, A.; Schnekenbuehl, S.; Dunger-Baldauf, C.; Rueegg, P.
PUB. DATE
December 2005
SOURCE
Gut;Dec2005, Vol. 54 Issue 12, p1707
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: It has been proposed that treatments for irritable bowel syndrome with constipation (lBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use. Aims: To evaluate the efficacy and safely of tegaserod on lBS symptoms, and its impact on quality of life and health economic measures. Patients: Women (⩾18 years of age) with lBS-C according to the Rome II criteria. Methods: Prospective, double blind, placebo controlled, randomised trial. Women with lBS-C either received tegaserod 6 mg twice daily or placebo for one month. Patients with at least a partial response entered a treatment free interval. Upon symptom recurrence, tegaserod treated patients were re-randomised to tegaserod or placebo for an additional month. Primary efficacy variables were response (overall lBS symptoms and abdominal discomfort/pain) to first and repeated treatment. Analysis was by intention to treat. Results: 2660 patients and 1191 patients were randomised for first and repeated treatment respectively. Tegaserod was superior to placebo for each primary efficacy variable (first treatment: 33.7% v 24.2% responders respectively for relief of lBS symptoms and 31.3% v 22.1% for relief of abdominal discomfort/ pain; repeated treatment: 44.9% v 28.7%, and 42.4% v 27.1%, all p<0.0001). Tegaserod was superior to placebo for every secondary efficacy variable (relief of abdominal discomfort/pain, bloating and constipation; stool frequency and consistency). A response to tegaserod was observed within the first treatment week. Tegaserod produced greater satisfaction, work productivity, and improved quality of life than placebo (p<0.05). Conclusion: Tegaserod provides rapid and sustained relief of lBS-C symptoms both during first and repeated treatment.
ACCESSION #
19160191

 

Related Articles

  • Review: Tegaserod prompts global relief of symptoms in the irritable bowel syndrome. Irvine, E. Jan // ACP Journal Club;Sep/Oct2004, Vol. 141 Issue 2, p44 

    This article focuses on the usage of tegaserod in treatment of Irritable Bowel Syndrome (IBS). The rates of response from reference group patients of relief were greater in the tegaserod groups (at each dose and with both doses combined) than in the corresponding placebo groups. Most patients...

  • Lubiprostone In Constipation-Predominant Irritable Bowel Syndrome. Carter, Natalie J.; Scott, Lesley J. // Drugs;2009, Vol. 69 Issue 9, p1229 

    â–² Lubiprostone is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of human gastrointestinal epithelial cells, thereby increasing chloride-rich fluid secretion. Although the mechanism is unclear, this may then decrease intestinal...

  • Placebo acupuncture improved symptoms and quality of life in irritable bowel syndrome. Kaptchuk, T. J. // Evidence Based Medicine;Dec2008, Vol. 13 Issue 6, p180 

    Design: randomised controlled trial (RCT). Allocation: concealed. Blinding: blinded (patients, outcome assessors, {data collectors, and data analysts}t). Setting: academic medical centre {in Boston, MA, USA}. Patients: 262 patients (mean age 39 y, 76% women) who had irritable bowel syndrome...

  • Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial. Chey, William D.; Paré, Pierre; Viegas, Andrea; Ligozio, Gregory; Shetzline, Michael A. // American Journal of Gastroenterology;May2008, Vol. 103 Issue 5, p1217 

    OBJECTIVES: Though the greatest proportion of irritable bowel syndrome (IBS) patients report a mixed bowel pattern (IBS-Mixed), no available therapies have been rigorously evaluated in this subgroup. This study aimed to evaluate the efficacy and safety of the 5-HT4 agonist tegaserod in women...

  • Adequate Relief in a Treatment Trial With IBS Patients: A Prospective Assessment. Passos, Maria C. F.; Lembo, Anthony J.; Conboy, Lisa A.; Kaptchuk, Ted J.; Kelly, John M.; Quilty, Mary T.; Kerr, Catherine E.; Jacobson, Eric E.; Rong Hu; Friedlander, Elizabeth; Drossman, Douglas A. // American Journal of Gastroenterology;Apr2009, Vol. 104 Issue 4, p912 

    OBJECTIVES:Adequate relief (AR) of irritable bowel syndrome (IBS) symptoms (IBS-AR) has been used as a primary end point in many randomized controlled trials of IBS and is considered by the Rome III committee to be an acceptable primary end point. However, controversy exists on whether baseline...

  • Soothing irritable bowel syndrome. Greenhalgh, Trisha // Accountancy;Jan2009, Vol. 142 Issue 1385, p44 

    This article reports on the treatment of irritable bowel syndrome (IBS). The article discusses IBS in terms of loose bowels, constipation, and pain and bloating, noting that symptoms can be worsened by painkillers, antibiotics, and antidepressants. Peppermint oil can be used to relieve these...

  • Identification of Patients with Non-D, Non-C Irritable Bowel Syndrome and Treatment with Renzapride: An Exploratory, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. R. Spiller; N. Meyers; R. Hickling // Digestive Diseases & Sciences;Dec2008, Vol. 53 Issue 12, p3191 

    Abstract  This was an exploratory study of renzapride in 168 male and female patients with non-D, non-C irritable bowel syndrome (IBS). Patients were randomized to placebo or renzapride (1, 2, or 4 mg/day) for 8 weeks. The primary efficacy variable was patient-reported satisfactory...

  • IBS - allergy - and the perception of pain.  // Foods Matter (USA);Mar2008, p16 

    The article reports on various studies related to the irritable bowel syndrome (IBS), allergy and the perception of pain. One study found that the likelihood of IBS was significantly high in patients with seasonal allergic rhinitis and allergic eczema. Another research suggests that the brains...

  • Gut feeling. Doheny, Kathleen // Natural Health;Jun2010, Vol. 40 Issue 5, p46 

    The article presents information on the natural remedies for irritable bowel syndrome (IBS). It is said that about 20% of people in the U.S. suffer with IBS and most of them are shy about talking to a doctor about their problem. The symptoms of IBS include constipation, diarrhea and abdominal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics